Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NBRV vs. OGI, DMAC, CYBN, FDMT, SLN, TLSA, INMB, ACIU, PBYI, and NLTXShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Organigram (OGI), DiaMedica Therapeutics (DMAC), Cybin (CYBN), 4D Molecular Therapeutics (FDMT), Silence Therapeutics (SLN), Tiziana Life Sciences (TLSA), INmune Bio (INMB), AC Immune (ACIU), Puma Biotechnology (PBYI), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Its Competitors Organigram DiaMedica Therapeutics Cybin 4D Molecular Therapeutics Silence Therapeutics Tiziana Life Sciences INmune Bio AC Immune Puma Biotechnology Neoleukin Therapeutics Organigram (NASDAQ:OGI) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Does the media prefer OGI or NBRV? In the previous week, Organigram had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Organigram and 0 mentions for Nabriva Therapeutics. Organigram's average media sentiment score of 1.71 beat Nabriva Therapeutics' score of 0.00 indicating that Organigram is being referred to more favorably in the media. Company Overall Sentiment Organigram Very Positive Nabriva Therapeutics Neutral Which has better valuation & earnings, OGI or NBRV? Organigram has higher revenue and earnings than Nabriva Therapeutics. Nabriva Therapeutics is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram$194.09M0.97-$33.39M$0.1014.00Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Do institutionals and insiders believe in OGI or NBRV? 34.6% of Organigram shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 0.1% of Organigram shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer OGI or NBRV? Nabriva Therapeutics received 195 more outperform votes than Organigram when rated by MarketBeat users. However, 70.71% of users gave Organigram an outperform vote while only 54.28% of users gave Nabriva Therapeutics an outperform vote. CompanyUnderperformOutperformOrganigramOutperform Votes19870.71% Underperform Votes8229.29% Nabriva TherapeuticsOutperform Votes39354.28% Underperform Votes33145.72% Do analysts prefer OGI or NBRV? Given Nabriva Therapeutics' higher possible upside, analysts clearly believe Nabriva Therapeutics is more favorable than Organigram.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is OGI or NBRV more profitable? Organigram has a net margin of -31.69% compared to Nabriva Therapeutics' net margin of -148.11%. Organigram's return on equity of -8.59% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organigram-31.69% -8.59% -6.54% Nabriva Therapeutics -148.11%-365.53%-135.81% Which has more risk & volatility, OGI or NBRV? Organigram has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. SummaryOrganigram beats Nabriva Therapeutics on 12 of the 17 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E Ratio0.008.5527.1919.64Price / SalesN/A262.61408.78152.17Price / CashN/A65.8538.3234.64Price / BookN/A6.536.974.60Net Income-$57.19M$143.48M$3.23B$248.06M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070OGIOrganigram0.627 of 5 stars$1.31-3.0%N/A-8.7%$180.74M$194.09M-3.45860News CoveragePositive NewsDMACDiaMedica Therapeutics1.3182 of 5 stars$4.17+1.5%$8.00+91.8%+55.4%$178.82MN/A-7.4520Short Interest ↑CYBNCybin2.7708 of 5 stars$8.10+1.8%$86.00+961.7%N/A$173.96MN/A-1.8550News CoverageAnalyst RevisionFDMT4D Molecular Therapeutics2.9049 of 5 stars$3.75+3.6%$29.56+688.1%-81.3%$173.72M$23K-1.32120Analyst ForecastAnalyst RevisionSLNSilence Therapeutics3.0617 of 5 stars$5.73-1.9%$33.83+490.5%-73.1%$171.50M$27.70M-3.65100News CoveragePositive NewsAnalyst ForecastGap UpTLSATiziana Life Sciences1.3674 of 5 stars$1.44+5.9%N/A+74.0%$168.26MN/A0.008News CoveragePositive NewsGap UpINMBINmune Bio2.0771 of 5 stars$7.19-2.6%$22.80+217.1%-9.5%$165.26M$50K-3.3010News CoveragePositive NewsACIUAC Immune3.003 of 5 stars$1.65-3.8%$12.00+629.5%-55.4%$165.17M$28.30M-3.58140Positive NewsPBYIPuma Biotechnology4.1084 of 5 stars$3.29+0.3%$7.00+112.8%-1.0%$163.29M$232.71M6.85200NLTXNeoleukin TherapeuticsN/A$17.01-9.2%N/A-43.7%$159.86MN/A-5.4790Gap UpHigh Trading Volume Related Companies and Tools Related Companies OGI Alternatives DMAC Alternatives CYBN Alternatives FDMT Alternatives SLN Alternatives TLSA Alternatives INMB Alternatives ACIU Alternatives PBYI Alternatives NLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBRV Stock Free NBRV Stock Alerts